Hebatullah A.Z.E. Abdelazim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Hebatullah A.Z.E. Abdelazim has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Abdulkarim Hasan
Department of Pathology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
1 shared publication - Ahmed Abdulwahab Bawahab
Department of Basic Medical Sciences, Pathology Division, College of Medicine, University of Jeddah, Jeddah 23890, Saudi Arabia
1 shared publication Amany I.A. Abo-Saif
Pathology department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt
1 shared publication- Amira N. Ismail
Pathology department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt
1 shared publication - Asmaa A.M. Moussa
Pathology Department, Nasr City Cancer Center, Cairo, Egypt
1 shared publication - Diaa Ashmawy
Pathology Department, Faculty of Medicine, Al-Azhar University, Damietta, Egypt
1 shared publication
Latest Publications
- Open Access
- 1 August 2024
- Published by International Society of Communication and Development Between Universities (ISCDBU) in Journal of Medicinal and Chemical Sciences
- Vol. 7 (8) , 998-1010
Assessment of Immunohistochemical Expression of Cyclin D1 and E-Cadherin in Laryngeal Squamous Cell Carcinoma
Laryngeal cancer, particularly the squamous cell carcinoma subtype, is prevalent all over the world and is characterized by a poor prognosis and high mortality rates. Currently, no definitive prognostic markers exist for predicting the behavior of the tumor. The aim of this study is to examine the correlation between cyclin D1 and E-cadherin expression with some clinicopathological parameters in laryngeal squamous cell carcinoma (LSCC). 60 cases of LSCC were retrospectively studied concerning the clinicopathological features and the potential prognostic role of cyclin D1 and E-cadherin expression in laryngeal carcinoma, using immunohistochemical staining scores on paraffin-embedded cancer tissues from patients who were treated with surgical excision. Reduced E-cadherin expression was significantly correlated with tumor grade (p = 0.0288), T stage (p = 0.041), and lymph node metastasis (p = 0.003). Regarding Cyclin D1, a statistically significant correlation was found with lymph node metastasis (p=0.019). In contrast, cyclin D1 expression was not significantly correlated with TNM stage or tumor grade (p=0.99 and 0.66, respectively). Evaluating expression of cyclin D1 in conjunction with E-cadherin expression in laryngeal squamous cell carcinoma may prove beneficial in identifying patients with lymph node metastasis. Tumor grade, stage, and nodal metastasis can significantly affect E-cadherin expression in patients with LSCC. However, further studies using genetic testing are recommended to assess the role of E-cadherin in tumor progression.
- 1 August 2024
- Published by International Society of Communication and Development Between Universities (ISCDBU) in Journal of Medicinal and Chemical Sciences
- Vol. 7 (8) , 998-1010
Open AccessAssessment of Immunohistochemical Expression of Cyclin D1 and E-Cadherin in Laryngeal Squamous Cell Carcinoma
Laryngeal cancer, particularly the squamous cell carcinoma subtype, is prevalent all over the world and is characterized by a poor prognosis and high mortality rates. Currently, no definitive prognostic markers exist for predicting the behavior of the tumor. The aim of this study is to examine the correlation between cyclin D1 and E-cadherin expression with some clinicopathological parameters in laryngeal squamous cell carcinoma (LSCC). 60 cases of LSCC were retrospectively studied concerning the clinicopathological features and the potential prognostic role of cyclin D1 and E-cadherin expression in laryngeal carcinoma, using immunohistochemical staining scores on paraffin-embedded cancer tissues from patients who were treated with surgical excision. Reduced E-cadherin expression was significantly correlated with tumor grade (p = 0.0288), T stage (p = 0.041), and lymph node metastasis (p = 0.003). Regarding Cyclin D1, a statistically significant correlation was found with lymph node metastasis (p=0.019). In contrast, cyclin D1 expression was not significantly correlated with TNM stage or tumor grade (p=0.99 and 0.66, respectively). Evaluating expression of cyclin D1 in conjunction with E-cadherin expression in laryngeal squamous cell carcinoma may prove beneficial in identifying patients with lymph node metastasis. Tumor grade, stage, and nodal metastasis can significantly affect E-cadherin expression in patients with LSCC. However, further studies using genetic testing are recommended to assess the role of E-cadherin in tumor progression.